Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

@article{Marrero2018DiagnosisSA,
  title={Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases},
  author={Jorge Marrero and Laura Kulik and Claude B. Sirlin and Andrew X. Zhu and Richard S. Finn and Michael M I Abecassis and Lewis Rowland Roberts and Julie K Heimbach},
  journal={Hepatology},
  year={2018},
  volume={68}
}
Author(s): Marrero, Jorge A; Kulik, Laura M; Sirlin, Claude B; Zhu, Andrew X; Finn, Richard S; Abecassis, Michael M; Roberts, Lewis R; Heimbach, Julie K 
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
Limited data exist on the burden and features of non‐cirrhotic hepatocellular carcinoma (HCC) in the United States.
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study
  • A. VitaleF. Farinati U. Cillo
  • Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2019
TLDR
The Italian Liver Cancer prognostic system for patients with hepatocellular carcinoma has recently been proposed and validated and the relationship among the ITA.LI.CA prognostic variables, treatment selection and survival outcome in HCC patients was explored.
The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
TLDR
This work aimed to investigate the usefulness of PIVKA‐II, AFP,AFP, AFP‐L3, CEA, and their combinations in the diagnosis of primary and metastatic HCC.
Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention
TLDR
This manuscript reviews the various treatment options for HCC with a historically noncurative intent.
A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid‐Enhanced MRI Features
Current major guidelines for diagnosis of hepatocellular carcinoma (HCC) based on imaging findings are different from each other and do not include clinical risk factors as a diagnostic criteria.
Frontiers of therapy for hepatocellular carcinoma
TLDR
This current review will highlight the new developments and future directions of hepatocellular carcinoma treatment and address the importance of a multidisciplinary approach to treatment.
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study
Recent studies link NAFLD to an increased incidence of HCC and extrahepatic cancers. However, earlier studies were small or lacked liver histology, which remains the gold standard for staging NAFLD
...
...

References

SHOWING 1-10 OF 194 REFERENCES
AASLD guidelines for the treatment of hepatocellular carcinoma
TLDR
This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Management of hepatocellular carcinoma: An update
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged
Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C
Background : Screening for hepatocellular carcinoma in cirrhotic patients using abdominal ultrasonography and alpha‐foetoprotein levels is widely practiced.
Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America
  • A. ChanD. Balderramo J. Debes
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis
Abdominal ultrasound fails to detect over one‐fourth of hepatocellular carcinoma (HCC) at an early stage in patients with cirrhosis. Identifying patients in whom ultrasound is of inadequate quality
Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease‐free survival
The aim of this study is to identify the efficacy of portal vein embolization (PVE) before right hepatectomy in patients with hepatocellular carcinoma (HCC) with regard to hepatic function, surgical
Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma
Background and Aim:  Patients with hepatocellular carcinoma (HCC) that is refractory to repeated transarterial chemoembolization (TACE) are considered for systemic therapy, but TACE refractoriness is
Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra‐arterial Therapy
  • J. H. SohnR. Duran J. Geschwind
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma
  • F. KolligsJ. Bilbao B. Sangro
  • Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2015
TLDR
To compare selective internal radiation therapy with transarterial chemoembolization (TACE), the standard‐of‐care for intermediate‐stage unresectable, hepatocellular carcinoma (HCC), as first‐line treatment, selectiveinternal radiation therapy (SIRT) is compared with TACE.
...
...